04:26 AM EDT, 08/07/2024 (MT Newswires) -- Myriad Genetics ( MYGN ) reported Q2 adjusted earnings late Tuesday of $0.05 per diluted share, compared with an adjusted loss of $0.08 a year earlier.

Analysts surveyed by Capital IQ expected a loss of $0.01.

Testing revenue for the quarter ended June 30 was $211.5 million, up from $183.5 million a year earlier.

Analysts surveyed by Capital IQ expected $205 million.

The company now expects full-year 2024 adjusted earnings of $0.08 to $0.12 per share, compared with the previous guidance of breakeven to adjusted EPS of $0.05. Analysts surveyed by Capital IQ expect $0.03.

Revenue for the year is projected to be $835 million to $845 million, versus the prior guidance of $820 million to $840 million. Analysts surveyed by Capital IQ expect $834.6 million.